Duncan Bridgeman
|
Friday 14th November 2003 |
Text too small? |
However, a policy change in accounting for foreign exchange hedges made comparisons with the same period a year ago misleading.
F&P Healthcare shares traded early yesterday at $12.05, down 20c since the interim profit announcement on Wednesday.
While net profit fell to $25.2 million, revenue growth from new products climbed 27% in US dollar terms, pushing operating revenue up 3.8% to a record $104.9 million.
The company is forecasting full year revenue of between $US120 million ($193.5 million) and $US125 million.
ABN Amro said in a research note it was reviewing its target price of $13.14 and its add recommendation on the stock. The broking house noted that the company's new obstructive sleep apnoea (OSA) flow generators would be fully established in the second half of the current financial year while its new mask products should continue to increase consumables market sha
No comments yet
NZK Market Update - Earnings Guidance Upgrade
MEL - Meridian Energy monthly operating report for March 2026
April 17th Morning Report
CCC - ESQUIRES IRELAND RECOGNISED AS THE BEST IN IRISH AWARDS
FBU - Fletcher Building Quarterly Volume Report for Q3 FY26
April 16th Morning Report
SCT - 2026 Half Year Announcement
Devon Funds Morning Note - 14 April 2026
BNP Paribas accredited as Derivatives Market Maker
GXH - Response to media report